Cilastatin/imipenem/relebactam

Drug Profile

Cilastatin/imipenem/relebactam

Alternative Names: Cilastatin/relebactam/imipenem; IMI/REL; Imipenem/cilastatin/relebactam; Imipenem/relebactam/cilastatin; MK-7655A; Relebactam + imepenem/cilastatin; Relebactam/cilastatin/imipenem; Relebactam/imipenem/cilastatin

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antibacterials; Azabicyclo compounds; Carbapenems; Cyclopropanes; Piperidines; Small molecules; Thienamycins
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors; Exopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bacterial infections; Intra-abdominal infections; Pneumonia; Urinary tract infections
  • Phase I Gram-negative infections

Most Recent Events

  • 04 Oct 2017 Phase-III clinical trials in Intra-abdominal infections in Japan (IV) (NCT03293485)
  • 04 Oct 2017 Phase-III clinical trials in Urinary tract infections in Japan (IV) (NCT03293485)
  • 18 Sep 2017 Merck completes a phase III trial in Bacterial infections (Treatment-resistant) in Brazil, Colombia, Estonia, Germany, Italy, Peru, Romania, Latvia, Greece, Lithuania, South Korea and Turkey (IV) (NCT02452047)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top